Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRSP CRISPR Therapeutics AG
- Stocks
- Healthcare
- NASDAQ: CRSP
Price (delayed)
$36.31
Market cap
$3.14B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.5
Enterprise value
$3.11B
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that
Highlights
The debt has declined by 7% year-on-year
The company's gross profit has shrunk by 86% YoY
The revenue has dropped by 86% year-on-year
Key stats
What are the main financial stats of CRSP
Market
Valuations
Earnings
Shares outstanding
86.36M
Market cap
$3.14B
Enterprise value
$3.11B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
82.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
82.6
Revenue
$37.68M
Gross profit
$37.68M
Operating income
-$474.4M
Net income
-$385.66M
EBIT
-$381.69M
EBITDA
-$362.52M
Free cash flow
-$307.86M
Per share
Balance sheet
Liquidity
EPS
-$4.5
EPS diluted
-$4.5
Free cash flow per share
-$3.58
Book value per share
$21.33
Revenue per share
$0.44
TBVPS
$25.21
Total assets
$2.17B
Total liabilities
$336.94M
Debt
$219.36M
Equity
$1.83B
Working capital
$1.75B
Debt to equity
0.12
Current ratio
15.64
Quick ratio
15.6
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
-962.2%
Gross margin
100%
Net margin
-1,023.6%
Operating margin
-1,259.2%
Return on assets
-17.1%
Return on equity
-20.1%
Return on invested capital
-18.6%
Return on capital employed
-18.6%
Return on sales
-1,013.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRSP stock price
How has the CRISPR Therapeutics AG stock price performed over time
Intraday
1.99%
1 week
0.47%
1 month
-6.78%
1 year
-36.25%
YTD
-7.75%
QTD
6.7%
Financial performance
How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$37.68M
Gross profit
$37.68M
Operating income
-$474.4M
Net income
-$385.66M
Gross margin
100%
Net margin
-1,023.6%
The company's gross profit has shrunk by 86% YoY
The revenue has dropped by 86% year-on-year
The company's net income has shrunk by 78% YoY and by 5% QoQ
The company's operating income has shrunk by 59% YoY
Price vs fundamentals
How does CRSP's price correlate with its fundamentals
Growth
What is CRISPR Therapeutics AG's growth rate over time
Valuation
What is CRISPR Therapeutics AG stock price valuation
P/E
N/A
P/B
1.7
P/S
82.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
82.6
The EPS has dropped by 67% year-on-year and by 3.7% since the previous quarter
The price to book (P/B) is 43% lower than the 5-year quarterly average of 3.0 and 11% lower than the last 4 quarters average of 1.9
The equity has decreased by 12% YoY and by 5% QoQ
The price to sales (P/S) is 94% lower than the 5-year quarterly average of 1305.7 but 58% higher than the last 4 quarters average of 52.3
The revenue has dropped by 86% year-on-year
Efficiency
How efficient is CRISPR Therapeutics AG business performance
The company's return on assets has shrunk by 76% YoY and by 8% QoQ
The ROE has plunged by 73% YoY and by 9% from the previous quarter
The ROIC has shrunk by 59% YoY and by 2.8% QoQ
The return on sales has declined by 4.2% since the previous quarter
Dividends
What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRSP.
Financial health
How did CRISPR Therapeutics AG financials performed over time
CRISPR Therapeutics AG's current ratio has decreased by 29% from the previous quarter and by 12% YoY
CRSP's quick ratio is down by 29% QoQ and by 12% YoY
The debt is 88% smaller than the equity
The equity has decreased by 12% YoY and by 5% QoQ
CRSP's debt to equity is up by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.